• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA)

    Simply Wall St·04/10/2026 00:38:14
    Listen to the news
    • Natera recently received a favorable ruling from the U.S. District Court in Delaware, which upheld the validity of its three asserted MRD patents and granted a 30% ongoing royalty on certain post-injunction revenues from infringing MRD-related product sales by ArcherDx and Invitae.
    • This court decision reinforces Natera’s intellectual property strength in molecular residual disease testing, potentially improving the company’s competitive position and revenue visibility in this specialized diagnostics segment.
    • Next, we’ll examine how this strengthened MRD patent position could influence Natera’s investment narrative and long-term molecular diagnostics ambitions.

    The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Natera Investment Narrative Recap

    To own Natera, you need to believe molecular diagnostics, especially Signatera in MRD, can support sustained test volume growth and a path to profitability despite ongoing losses. The Delaware ruling that affirms key MRD patents and grants a 30% royalty strengthens Natera’s IP position, but does not remove the immediate risks around high cash burn, execution on clinical trials and reimbursement, which still look like the key short term swing factors.

    The recent Clinical Cancer Research publication on Signatera in older women with ER+/HER2- breast cancer is especially relevant here, because it underscores MRD’s potential clinical utility in real decision making, not just trial settings. Together with the strengthened patent position, this kind of data could matter for future payer decisions and adoption trends, which many investors see as central catalysts over the next few years.

    Yet even with stronger patents, investors should still pay close attention to the risk that legal and regulatory pressures could...

    Read the full narrative on Natera (it's free!)

    Natera's narrative projects $3.8 billion revenue and $129.1 million earnings by 2029.

    Uncover how Natera's forecasts yield a $259.11 fair value, a 28% upside to its current price.

    Exploring Other Perspectives

    NTRA 1-Year Stock Price Chart
    NTRA 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming around US$3.4 billion of revenue and US$622.9 million of earnings by 2028, so this legal and MRD data news may either support that ambitious view or highlight how much still has to go right.

    Explore 6 other fair value estimates on Natera - why the stock might be worth 6% less than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Natera research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

    Contemplating Other Strategies?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.